{"transactions":[{"id":3620482,"issuer":{"id":6521,"kind":"organization","name":"LifeMD, Inc."},"owners":[{"id":159638,"kind":"person","name":"Kalkstein Robert L","position":1,"cik":"0001526136","reported_name":"Kalkstein Robert L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Options to purchase Common Stock","published_at":"2019-03-04T11:03:52.000Z","date":"2019-03-01","kind":"other","acquired":true,"shares":150000,"price":0.28,"value":42000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to an amendment to his consulting agreement with Conversion Labs, Inc., the exercise price of these options were reduced from $0.40 to $0.28 and now vest on March 31, 2019. Additionally, the 200,000 to be issued to Mr. Kalkstein pursuant to his consulting agreement were cancelled and Mr. Kalkstein also has forgone $32,500 owed to him by Conversion Labs, Inc."}],"balance_after":150000,"derivative":{"exercise_price":0.28,"exercise_date":"2019-03-31","expiration_date":"2027-09-30","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001213900-19-003447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/948320/000121390019003447/ownership.xml","form_type":"4"}},{"id":3620481,"issuer":{"id":6521,"kind":"organization","name":"LifeMD, Inc."},"owners":[{"id":159638,"kind":"person","name":"Kalkstein Robert L","position":1,"cik":"0001526136","reported_name":"Kalkstein Robert L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Options to purchase Common Stock","published_at":"2019-03-04T11:03:52.000Z","date":"2017-10-01","kind":"other","acquired":true,"shares":150000,"price":0.28,"value":42000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These options were previously reported by Mr. Kalkstein on his Form 3 filed with the Commission on November 13, 2017. Pursuant to an amendment to his consulting agreement with Conversion Labs, Inc., the exercise price of these options were reduced from $0.40 to $0.28."}],"balance_after":150000,"derivative":{"exercise_price":0.28,"exercise_date":"2017-10-01","expiration_date":"2027-09-30","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001213900-19-003447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/948320/000121390019003447/ownership.xml","form_type":"4"}}]}